^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ituxredi (rituximab biosimilar)

    i
    Other names: DRL_RI
    Associations

    News

    Trials
    Company:
    Abbott, CinnaGen, Dr. Reddy’s, EMD Serono, Fresenius Kabi, R-Pharm
    Drug class:
    CD20 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera® in low-tumor-burden follicular lymphoma: the FLINTER study. (PubMed, Ther Adv Med Oncol)
    The study demonstrated efficacy equivalence of DRL_RI to MabThera; with comparable safety, immunogenicity, serum concentrations, and PD between groups. This trial was registered at ClinicalTrials.gov identifier: NCT03976102 and EudraCT (2018-004223-36).
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Ituxredi (rituximab biosimilar)
    almost2years
    FLINTER: Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (clinicaltrials.gov)
    P3, N=317, Completed, Dr. Reddy's Laboratories Limited | Active, not recruiting --> Completed
    Trial completion
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • Ituxredi (rituximab biosimilar)
    2years
    RI-01-007: A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products (clinicaltrials.gov)
    P3, N=140, Completed, Dr. Reddy's Laboratories Limited | Active, not recruiting --> Completed
    Trial completion
    |
    Ituxredi (rituximab biosimilar)
    2years
    Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era. (PubMed, Front Oncol)
    Reditux™ and Ristova were comparable in real-world setting. ISRCTN registry, identifier (ISRCTN13301166).
    Journal • Real-world evidence • Real-world
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Ituxredi (rituximab biosimilar)
    3years
    Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=39, Completed, UNC Lineberger Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Jul 2022
    Trial completion • Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Ituxredi (rituximab biosimilar)
    over3years
    FLINTER: Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (clinicaltrials.gov)
    P3, N=317, Active, not recruiting, Dr. Reddy's Laboratories Limited | Recruiting --> Active, not recruiting | Trial completion date: Sep 2020 --> Mar 2023 | Trial primary completion date: Sep 2020 --> Sep 2022
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Ituxredi (rituximab biosimilar)
    4years
    Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Dec 2022 --> Jul 2024 | Trial primary completion date: Mar 2021 --> Jul 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Ituxredi (rituximab biosimilar)
    almost5years
    Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Ituxredi (rituximab biosimilar)